Visceral fat is very common among women, especially among women past the age of 40 years old. While shedding the fat can be hard, a certain kind of diet can help reduce the visceral fat.
Visceral fat is the fat stored around the abdomen. It is also more dangerous because it is stored near the major organs of the body. The liver, intestines, and stomach are likely to get affected by visceral fat and if it continues to build up, it can result in dangerous or even fatal health conditions, such as type 2 diabetes and cardiovascular disease.
This is why making changes in the food being eaten is important in order to reduce the visceral fat and keep it from building up.
There are many kinds of diets that are introduced to the world today. Apart from vegan and vegetarian diets, there is also paleo, gluten-free, and keto. All of these diet plans seem to help people in losing weight, but when it comes to losing visceral fat in the body, the diet plan that seems to work is a low-carb diet.
Low-carb diets seem to prove more effective than low-fat diets. Many studies have proven this to be an effective way to shed the visceral fat around the abdomen. Getting into the specifics, the diet plan that can help reduce the visceral fat is known at the ketogenic or keto diet. This particular diet plan is very low in carbohydrates. This diet significantly decreases the intake of carbs, replacing it with fat and resulting in the body being placed in a state called ketosis.
A study was conducted regarding the keto diet. 28 people who were overweight and obese were tasked to follow diet plans. The result was that those who followed a ketogenic diet ended up losing more visceral fat than those who were following a diet that is low in fat. To add to that, those who followed the ketogenic diet were even eating more than 300 calories more every day.
Although the ketogenic diet is proven to be effective in shedding visceral fat, it generally helps in weight loss overall.


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



